Agur; Zvia

Patent Applications and Registrations

Patent applications and USPTO patent grants for Agur; Zvia.The latest application filed is for "method and system for prediction of medical treatment effect".

Company Profile

0.15.13

Agur; Zvia - Tel-Aviv IL
Agur; Zvia - Ramat Gan N/A IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method and system for prediction of medical treatment effect Grant 11,145,417 - Kheifetz , et al. October 12, 2	2021-10-12
Method And System For Prediction Of Medical Treatment Effect App 20170140109 - KHEIFETZ; Yuri ; et al.	2017-05-18
Therapeutic implications of dickkopf affecting cancer stem cell fate Grant 8,762,069 - Agur , et al. June 24, 2	2014-06-24
System and method of evaluation of stochastic interactions of a soluble ligand with a target cell population for optimization of drug design and delivery Grant 8,650,017 - Kirnasovsky , et al. February 11, 2	2014-02-11
System and methods for optimized drug delivery and progression of diseased and normal cells Grant 8,504,303 - Agur , et al. August 6, 2	2013-08-06
Techniques for purposing a new compound and for re-purposing a drug Grant 8,489,336 - Arakelyan , et al. July 16, 2	2013-07-16
System And Methods For Optimized Drug Delivery And Progression Of Diseased And Normal Cells App 20120284005 - AGUR; Zvia ; et al.	2012-11-08
Cancer Therapy By Docetaxel And Granulocyte Colony-stimulating Factor (g-csf) App 20110286960 - Vainas; Oded ; et al.	2011-11-24
System and methods for optimized drug delivery and progression of diseased and normal cells Grant 8,055,491 - Agur , et al. November 8, 2	2011-11-08
Interactive technique for optimizing drug development from the pre-clinical phases through phase-IV Grant 7,970,550 - Arakelyan , et al. June 28, 2	2011-06-28
Therapeutic Implications Of Dickkopf Affecting Cancer Stem Cell Fate App 20100235150 - AGUR; Zvia ; et al.	2010-09-16
Techniques for Purposing a New Compound and for Re-Purposing a Drug App 20100161301 - ARAKELYAN; Levon ; et al.	2010-06-24
Treatment Protocol Generation For Diseases Related To Angiogenesis App 20080275684 - Agur; Zvia ; et al.	2008-11-06
Treatment protocol generation for diseases related to angiogenesis Grant 7,418,374 - Agur , et al. August 26, 2	2008-08-26
System and Methods for Optimized Drug Delivery and Progression of Diseased and Normal Cells App 20070213961 - Agur; Zvia ; et al.	2007-09-13
System and methods for optimized drug delivery and progression of diseased and normal cells Grant 7,266,483 - Agur , et al. September 4, 2	2007-09-04
System and method of evaluation of stochastic interactions of a soluble ligand with a target cell population for optimization of drug design and delivery App 20070054331 - Kirnasovsky; Oleg U. ; et al.	2007-03-08
System and methods for optimized drug delivery and progression of diseased and normal cells Grant 7,133,814 - Agur , et al. November 7, 2	2006-11-07
System and methods for optimized drug delivery and progression of diseased and normal cells App 20060167637 - Agur; Zvia ; et al.	2006-07-27
System and methods for optimized drug delivery and progression of diseased and normal cells Grant 6,871,171 - Agur , et al. March 22, 2	2005-03-22
Interactive technique for optimizing drug development from the pre-clinical phases through phase-IV App 20040107084 - Arakelyan, Levon ; et al.	2004-06-03
System and methods for optimized drug delivery and progression of diseased and normal cells App 20030097220 - Agur, Zvia ; et al.	2003-05-22
Treatment protocol generation for diseases related to angiogenesis App 20030088237 - Agur, Zvia ; et al.	2003-05-08
System and methods for optimized drug delivery and progression of diseased and normal cells App 20020095258 - Agur, Zvia ; et al.	2002-07-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.